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Helicobacter pylori (H. pylori) is a gram negative spiral rod bacterium which inhabits gastric 
mucosa and attaches to the gastric epithelium using specific receptor. H. pylori infection 
endures as one of the most challenging diseases triggering high mortality and morbidity. H. 
pylori infection is reported as the cause of gastric cancer, chronic gastritis, peptic ulcer and other 
gastrointestinal disorders. It was suggested that long-term H. pylori infection may aggravate 
chronic kidney disease (CKD) complications and cardiovascular disease (CVD) risk factors. 
Patients with chronic renal failure often possess gastrointestinal symptoms including decline 
of gastrointestinal motility, amyloid protein deposition and decreased sensory disturbance. 
Hence, in patients with chronic renal failure, the nutrition status is pour which usually leads 
to the development of malnutrition. This status will increase the morbidity and mortality of 
these patients. These patients in comparison to individuals with normal renal function usually 
have higher risks of gastric mucosal damage due to hypergastrinemia, enhanced inflammation, 
local chronic circulatory failure and high level of ammonia. Majority of these patients (25%–
75%) usually suffer from gastrointestinal complications such as gastric erosions, gastrointestinal 
bleeding, peptic ulcers and angiodysplasia. The aim of the present study was to review the 
relation between one of the most challenging diseases, called H. pylori infection, and end-stage 
renal disease (ESRD), diabetic and chronic hemodialysis individuals as well as presenting the 
treatment strategies of this infection.
Abstract
Citation: Ardalan MR, 
Mardani S, Asgari-
Savadjani S, Tamadon 
MR, Naghdifar S, 
Nasri H. An update 
on Helicobacter 
pylori infection in 
renal failure patients. 
Immunopathol Persa. 
2016;2(2):e10.
Immunopathologia Persa http www.immunopathol.comm
Introduction
Helicobacter pylori (H. pylori) is a gram nega-
tive spiral rod bacterium which inhabits gas-
tric mucosa (1-4) and attaches to the gastric 
epithelium using specific receptor (5,6). H. 
pylori infection endures as one of the most 
challenging diseases triggering high mortal-
ity and morbidity (7,8). H. pylori infection 
is reported as the cause of gastric cancer, 
chronic gastritis, peptic ulcer and other gas-
trointestinal disorders (9-13). Then, bacte-
rial infection is a basic problem in patients 
especially those who are hospitalized. Re-
cently, several reports have been published 
reporting the relation of H. pylori infection 
and kidney failure especially chronic renal 
failure or diabetes diseases. 
Chronic renal failure and gastrointestinal
Patients with chronic renal failure often pos-
sess gastrointestinal symptoms including 
Key point 
Helicobacter pylori (H. pylori) is a gram 
negative spiral rod bacterium which 
inhabits gastric mucosa and attaches to the 
gastric epithelium using specific receptor. 
H. pylori is one of the most challenging 
diseases which is important for public 
health. H. pylori infection endures as one 
of the most challenging diseases triggering 
high mortality and morbidity. H. pylori 
infection is reported as the cause of gastric 
cancer, chronic gastritis, peptic ulcer and 
other gastrointestinal disorders. It was 
suggested that long-term H. pylori infection 
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(CKD) complications and cardiovascular 
disease (CVD) risk factors.
decline of gastrointestinal motility, amyloid 
protein deposition and decreased sensory 
disturbance (14). Hence, in patients with 
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chronic renal failure, the nutrition status is pour which 
usually leads to the development of malnutrition. This 
status will increase the morbidity and mortality of these 
patients. These patients in comparison to individuals with 
normal renal function usually have higher risks of gastric 
mucosal damage due to hypergastrinemia, enhanced in-
flammation, local chronic circulatory failure and high lev-
el of ammonia. Majority of these patients (25%–75%) usu-
ally suffer from gastrointestinal complications such as gas-
tric erosions, gastrointestinal bleeding, peptic ulcers and 
angiodysplasia (15). The aim of the present review paper 
was to review the relation between one of the most chal-
lenging diseases, called H. pylori infection, and end-stage 
renal disease (ESRD), diabetic and chronic hemodialysis 
individuals as well as presenting the treatment strategies 
of this infection. 
Materials and Methods
This review article discusses recent findings on Helicobacter 
pylori infection in renal diseases. For this review, we used 
a variety of sources by searching through Web of Science, 
PubMed, EMBASE, Scopus and directory of open access 
journals (DOAJ). The search was performed using com-
binations of the following key words and or their equiva-
lents such as chronic renal failure, end-stage renal disease, 
Helicobacter pylori, diabetic nephropathy, chronic kidney 
disease and hemodialysis 
H. pylori infection in ESRD patients
The relationship between H. pylori infection and ESRD 
events remains unknown. The risk of ESRD noticeably is 
increased in patients with H. pylori infection combined 
with at least one of the following concomitant comorbidi-
ties: diabetes, hypertension, hyperlipidemia and coronary 
artery disease (1). H. pylori infection is one of the main 
factors for dyspepsia and recently has been investigated for 
in end-stage its possible role in renal disease. Dyspepsia is 
a pain in the upper part of the abdomen which is a usu-
al complication in chronic kidney disease (CKD) patients 
and dialysis patients (16). H. pylori infection was related to 
a subsequent risks of ESRD thus, it has been determined 
that H. pylori-infected patients with cardiovascular disease 
(CVD) or concomitant chronic kidney disease risk factors 
were at a higher risk of ESRD than those who had a sin-
gle CVD or CKD risk factor. Hence, it was suggested that 
long-term H. pylori infection augments various compli-
cations of CKD and CVD risk factors, causing a decrease 
in renal function followed by ESRD, as noticed in the H. 
pylori-infected group (1). H. pylori also plays an important 
role on the aggravation of complications of chronic hemo-
dialysis patients and its complications too (17). 
H. pylori infection in diabetic nephropathy, hemodialysis 
and chronic renal failure patients
H. pylori infection is common in diabetics specially is 
higher in patients with type-2 diabetes mellitus compared 
to normal population. In this regard, a study was done but 
no significant relation was found amongst the serum H. 
pylori IgG antibody titer and magnesium levels and the age 
of patients, duration of diabetes and creatinine clearance. 
There was just a positive correspondence between H. py-
lori infection and serum magnesium. They confirmed that 
this correspondence might facilitate the coloni zation of H. 
pylori in the stomach of patients on hemodialysis but not 
in patients with various stages of renal failure who were 
not undergoing hemodialysis (18).
In studies, the value of serum H. pylori specific IgG anti-
body value could be applicable because it is as a sign of H. 
pylori infection although some authors did not find any 
significant difference of various biochemical parameters 
between females and males, diabetics and non-diabetics 
and serum H. pylori IgG antibody titer. But they found 
significant negative relation between serum magnesium 
and serum intact PTH levels and serum H. pylori IgG anti-
body titer. Otherwise, some investigators found a positive 
correlation between H. pylori infection and serum magne-
sium. In this regard, to understand the worsening factors 
of H. pylori infection in chronic kidney disease, particular-
ly in hemodialysis patients, Hafizi et al conducted a study 
on 44 hemodialysis patients or other research on 94 type-2 
diabetic patients. They found a significant positive rela-
tion of serum magnesium with H. pylori antibody. Thus, it 
seems the presence of an association of H. pylori infection 
with serum magnesium. It is clear that magnesium ion at-
tainment is essential for H. pylori (19). In this regard, the 
high serum magnesium level in the gastric mucosa could 
facilitate the colonization of H. pylori in the stomach of 
patients on hemodialysis, but not in patients with different 
stages of renal failure that were not on hemodialysis (8, 
19). Conversely, magnesium is mostly excreted by kidney 
and magnesium metabolism is interrupted in patients with 
chronic renal failure. Actually, elevated serum magnesium 
level can be an obstacle in patients on maintenance hemo-
dialysis. Although, the kidneys are the major way of excre-
tion of magnesium from the body, increased serum mag-
nesium would be expected in hemodialysis patients and in 
patients with renal failure (19). 
In the report of Hosseini et al, it was shown that the oc-
currence of H. Pylori infection in renal transplant patients 
and the normal population is the same (20). Lately, many 
evidences have shown that H. pylori is associated with ex-
tra-gastrointestinal diseases including idiopathic throm-
bocytopenic purpura, iron deficiency anemia and diabetes 
mellitus. Also, patients with chronic renal failure usually 
suffer from local or systemic chronic circulatory failure or 
both of them, high ammonia, hypergastrinemia and im-
proved inflammation that facilitates H. pylori infection. 
Gu et al, investigated the association between infection of 
H. pylori and the different types of dialysis and then they 
found that H. pylori infection was not statistically relat-
ed to hemodialysis specifically. So, their results showed 
that prevalence of H. pylori infection was similar between 
chronic renal failure (CRF) patients who were receiving 
dialysis and the control cluster with normal renal function. 
Some investigators, however, realized that the prevalence 
of H. pylori in CRF patients suffering dialysis was consid-
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erably lower than in non-CRF controls without or with 
gastrointestinal symptoms (21-26). The fact is that the ma-
jority of CRF patients who receive dialysis inevitably have 
access to antibiotics, H2 receptor antagonists or proton 
pump inhibitors which then affect the H. pylori infection 
rate to some extent. Also, gastric atrophy progresses along 
with reduced secretion of acid in addition to higher levels 
of pro-inflammatory cytokines in CRF patients causing H. 
pylori infection difficult to survive (27,28).
Relation between H. pylori infection and urea 
concentration 
H. pylori is known to change acid secretory physiology in 
patients with chronic infection. Subsequent acid hyperse-
cretion and hypergastrinemia are key factors in the gas-
troduodenal lesions and pathophysiology of peptic ulcer 
disease in these patients and more evident in patients with 
ESRD. Therefore, detection and then treatment of gastro-
duodenal lesions are pretty important especially in pre-
venting the complications after renal transplantation. Var-
ious investigations were conducted to investigate whether 
urea concentration or uremia in gastric secretion causes 
an appropriate environment for infection of H. pylori (29-
33). However, on the other hand, other investigation have 
detected the frequency of H. pylori infection in uremia 
is 34%-47% and in kidney transplanted patients is 38%. 
Some studies have reported the frequency of H. pylori in-
fection in patients with ESRD on hemodialysis is 34%-75% 
(34). The majority of patients with ESRD on hemodialysis 
experienced gastrointestinal discomfort. It is assumed that 
uremia can alter the bacterial colonization of the upper 
gastrointestinal tract and hence, reducing infection of H. 
pylori (35). 
Relation between H. pylori infection and vitamin D 
level
25-hydroxy vitamin D (25-OH Vit D) is the main circulat-
ing metabolite of vitamin D even though the biologically 
active form of vita min D is 1,25(OH)2 vitamin D, made 
in the kidney, it is generally accepted that the amount of 
circulating 25-OH vitamin D provides better information 
with respect to the patients vitamin D status and is used 
for the finding of hypovitaminosis. Generally, the presence 
of the vitamin D receptor shows that cells are responsive 
to vitamin D. Apart from enterocytes, osteoblasts and dis-
tal renal tubular cells, the vitamin D receptors is found in 
lots of other cell types, including parathyroid gland cells, 
colon cells, skin keratinocytes, ovarian cells and pituitary 
gland cells. The vitamin D receptor is also generally ex-
pressed in most cell types of the immune system, i.e., B 
cells, T cells, macrophages, monocytes, dendritic cells and 
NK cells. It has been detected that high blood urea nitro-
gen values could associated with a low occurrence of H. 
Pylori infection, and that patients on hemodialysis could 
be protected against this infection due to state of immune 
deficiency. We previously shown the influence of serum 
25-hydroxy vitamin D levels on H. pylori infections in 36 
patients with end-stage kidney failure on regular hemo-
dialysis. The serum H. pylori specific IgG antibody values 
and serum 25-OH vitamin D level were assessed through 
an enzyme-linked immunosorbent assay (ELISA) method. 
The study patients were including 15 females and 21 males. 
The mean age of the study group was 47 (±17) years. The 
average level of serum 25-OH vitamin D was 0.5 ± 18.7 
nmol/l (median: 3.5 nmol/l) whereas the average value of 
serum H. pylori specific IgG antibody titer was 7.7 (±9.9) 
U/mL (median: 2 U/mL).Thus an important positive asso-
ciation was obtained amongst the levels of serum 25-OH 
vitamin D and serum H. pylori specific IgG antibody titers 
(data adjusted for age, urea reduction rate, duration and 
dose of dialysis) ( r = 0.36, P = 0.043). In this study, we sug-
gested that vitamin D could positively affect the chronic 
inflammatory status of dialysis patients and could poten-
tiate the immune response in such patients. According of 
this immuno-modulatory effect, vitamin D analogs could 
offer new means to control the inflammatory status in pa-
tients on upkeep dialysis (36). Moreover, in our another 
studies an inverse association of serum albumin with H. 
pylori IgG antibody level and dialysis efficacy as well as 
positive association of H. pylori IgG antibody level with 
the duration of hemodialysis treatment, were also detected 
which imply an inverse correlation of H. pylori infection 
with malnutrition and the resultant immuno-deficiency of 
hemodialysis patients (37-39). 
H. pylori infection and kidney transplantation 
Before the discovery of proton pump inhibitors and H2 
blockers, usually the H. pylori infected disease would lead 
to serious complications following kidney transplantation. 
Therefore, in some centers, ulcer surgery was advocated 
before kidney transplant. Following the introduction and 
usage of ranitidine as ulcer prophylaxis following kidney 
transplantation, the number of serious kidney and upper 
gastrointestinal complications decreased substantially (40). 
Nowadays, H. pylori is accepted as a major etiologic fac-
tor in gastritis and gastroduodenal ulceration. During an 
acute rejection episode effective ulcer prophylaxis seemed 
to be important in patients regardless of their H. pylori sta-
tus, especially in patients who were also receiving prophy-
lactic aspirin treatment. Some centers have suggested that 
although H. pylori infections are common in kidney trans-
plant patients, however these patients do not increase the 
risk of postoperative gastroduodenal complications (41). 
H. pylori infection and anemia
Anemia is a constant finding in renal disease, affecting 
about more than 90% of patients, and the major role of 
anemia in the expansion of cardiovascular dysfunction 
is founded, anemia of ESRD could be accomplished rel-
atively effectively by recombinant human erythropoietin. 
In this regard we previously conducted a cross-sectional 
study on maintenance hemodialysis patients. In this re-
search was examined the aggravation of anemia by H. py-
lori on 39 patients with ESRD undergoing routine hemo-
dialysis treatment. Average ages of patients were 46 (±18) 
years. All patients had dissimilar upper gastrointestinal 
Ardalan MR et al 
 Immunopathologia Persa  Volume 2, Issue 2, July 20164
complaints including epigastric burning, epigastric pain, 
early satiety, postprandial fullness, bloating and belching. 
The duration of hemodialysis was 30 (±35) months (medi-
an: 18 months). Mean ± SD of hematocrit and hemoglobin 
level of all patients were 28 ± 6% (median: 29%) and 9 ± 
2 g/dL (median: 9 g/dL) respectively. The rate of serum 
H. pylori particular IgG antibody titers of all patients was 
7.6 (±9.9) U/mL (median: 2 U/mL). In this examination 
no significant difference of H. pylori IgG antibody level 
amongst females and males or diabetic and non-diabet-
ic hemodialysis patients were seen. In this study in male 
cluster an important inverse relation amongst logarithm 
of H. pylori IgG antibody level and serum hematocrit and 
hemoglobin were understood. Furthermore, in this cluster 
an imperative inverse relation amongst logarithm of H. py-
lori IgG antibody level and serum iron were seen. Further-
more, no important relationship among serum H. pylori 
IgG antibody level and serum iron, hematocrit and hemo-
globin in all patients, female, diabetic and non-diabetics 
hemodialysis cluster were perceived. In this research no 
important relationship among serum H. pylori IgG anti-
body level and serum ferritin in all clusters was seen. Thus, 
it was shown that presence of H. pylori infection is relat-
ed to a poorer response to oral iron therapy which devel-
ops with treatment for H. pylori infection. In patients on 
regular hemodialysis could be shown an inverse relation 
amongst H. pylori infection with hematocrit and hemoglo-
bin level in addition to with serum iron, implies further 
attention to infection of H. pylori in these patients which 
one their major problem is anemia, so aggravation of H. 
pylori infection with anemia needs aggressive treatment of 
H. pylori infection in study patients (42). 
Diagnosis and treatment of H. pylori infection 
H. pylori infection can be diagnosed with both nonin-
vasive and invasive tests. Invasive tests include culture, 
histology and rapid urease test that require endoscopy 
to obtain biopsies of the gastric mucosa and noninvasive 
tests include analysis of samples of blood, stool or breath 
including urease breath test (UBT) and H. pylori stool an-
tigen (HPSA). Noninvasive tests are beneficial for primary 
diagnosis, when a treatment sign previously exists, or to 
monitor treatment success or failure. They are also bene-
ficial in patients who cannot tolerate endoscopy, children, 
and epidemiological population studies. These tests have 
been introduced as reliable tests to screen H. pylori infec-
tion until recently in patients with kidney failure (43). 
Amoxicillin (AMX) and clarithromycin (CAM) or met-
ronidazole (MNZ) are still used for treating of H. pylori 
infection. However, the efficiency of legacy triple regi-
mens has been really challenged, and they are progres-
sively becoming ineffective. Moreover, some areas in Asia 
show patterns of emerging antimicrobial resistance. More 
effective regimens such as the bismuth and non-bismuth 
quadruple, sequential, and dual-concomitant (hybrid) 
regimens are now substituting standard triple therapies as 
empirical first-line treatments on the base of the under-
standing of the local prevalence of H. pylori antimicrobial 
resistance (44). The North American Society and the Eu-
ropean Society of Pediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHAN) proposed for first-line thera-
py including triple therapy with a proton pump inhibitor 
(PPI) and Imidazole or Clarithromycin and Amoxicillin; 
therapy with bismuth salt, Imidazole and Amoxicillin; or 
sequential therapy (45). 
Conclusion
H. pylori is one of the most challenging diseases which 
is important for public health. H. pylori associates with 
ESRD, diabetic nephropathy and HD. Magnesium ion is 
essential for H. pylori to facilitate the colonization of this 
bacteria in the stomach of patients. However, urea concen-
tration relates to H. pylori as well. Uremia can change bac-
terial colonization of the upper gastrointestinal tract and 
then reduces H. pylori infection. So, we should be aware of 
H. pylori infection and try to diagnose and treat this dis-
ease at least time.
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